CRISPR Therapeutics (NasdaqGM:CRSP) experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics CRSP is currently the only company in the world to have secured approval for a CRISPR-based gene therapy ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 13.29%. Read on to learn why. Crispr Therapeutics AG has seen a notable increase in its stock ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

The global CRISPR technology market is expected to witness a growth rate of 16% in the next five years. Continuous ...

The CRISPR market is witnessing rapid growth due to its potential to transform gene therapy, diagnostics, and agriculture. With widespread research and commercial interest, the market is poised to ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

The Klinefelter syndrome (KS) therapeutics market is projected to grow at a CAGR of 6–8% during the forecast period driven by ...